Career Panel and Networking Event

Posted by ISPE Boston
On October 25, 2023

The Career Panel and Networking Event was hosted by Northeastern University’s Graduate Women in Science and Engineering, ISPE Boston’s Ethnocultural Diversity, Equity, and Inclusion Committee, and ISPE Boston’s Student Development Committee at Northeastern University. The event was attended by both undergraduate and graduate students who are interested in the biotech and pharma industries. During the […]

Product Show Attracts Thousands on September 20th

Posted by ISPE Boston
On October 19, 2023

Last month, on Wednesday, September 20th, 2023, we hosted our 31st Annual Product Show at Gillette Stadium! And honestly, it was the biggest, best show we have had yet. We are just now recovering. There was record attendance once again, beating out last year’s attendance with over 4,500 attendees! Our new mobile app helped people […]

New Map of the Brain to Help Treat Disease

Posted by ISPE Boston
On October 19, 2023

A group of international scientists have mapped the genetic, cellular, and structural makeup of the human brain and the nonhuman primate brain. This understanding of brain structure allows for a deeper knowledge of the cellular basis of brain function and dysfunction, helping pave the way for a new generation of precision therapeutics for people with […]

Vertex Researchers Awarded “Breakthrough Prize in Life Sciences”

Posted by ISPE Boston
On October 12, 2023

Three Vertex researchers have been awarded the 2024 Breakthrough Prize in Life Sciences “for developing life-transforming drug combinations that repair the defective chloride channel protein in patients with cystic fibrosis.” The award celebrates the work of Paul Negulescu, Ph.D., Fredrick Van Goor, Ph.D., and Sabine Hadida, Ph.D., who have worked together to lead cystic fibrosis […]

Sanofi and Teva to Collaborate on Treatment for Inflammatory Bowel Disease

Posted by ISPE Boston
On October 12, 2023

Sanofi and Teva Pharmaceuticals have entered into a collaboration to co-develop and co-commercialize TEV’574, currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn’s disease, two types of inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. An estimated 10 million people worldwide live with IBD. According to […]

Chapter Member Anniversaries: October 2023

Posted by ISPE Boston
On October 4, 2023

Please congratulate the following members celebrating milestone anniversaries in October 2023. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Mark Caswell, Lonza Biologics Inc Louis Cicchese, Moderna Therapeutics Aaron Conant, Alnylam Pharmaceuticals Patrick Cunneen, Techniserv Inc William Devine, Pharma-Tech Services Jason Dollarhide, Hodess Cleanroom Construction Peter Falk, […]

Welcome New Members September 2023!

Posted by ISPE Boston
On October 2, 2023

We would like to introduce the Members who joined ISPE in September 2023, welcome them to the Chapter and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]

Alnylam Drug Moves Forward at FDA

Posted by ISPE Boston
On September 14, 2023

RNAi therapeutics company Alnylam Pharmaceuticals welcomed the positive outcome of the FDA advisory committee meeting. On Wednesday the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9:3 that the benefits of RNAi therapeutic patisiran outweigh its risks for the treatment of the cardiomyopathy of ATTR amyloidosis. The CRDAC provides the FDA with independent, expert advice and recommendations […]

FDA Approves BioLineRx Drug for Multiple Myeloma

Posted by ISPE Boston
On September 14, 2023

Biopharma BioLineRx, headquartered in Israel with a Waltham presence, has announced FDA approval for Aphexda, the company’s first approved therapeutic. The drug helps physicians harvest stem cells for the treatment of multiple myeloma, the second most-common hematologic malignancy. Autologous stem cell transplantation (ASCT) is part of the standard of care treatment for multiple myeloma and […]

Moderna Enters New Partnership in Deal Worth Up to $1.8 Billion

Posted by ISPE Boston
On September 14, 2023

Moderna has announced it will partner with German biotech Immatics in a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need. This broad multi-platform collaboration will leverage the deep scientific expertise and core operational capabilities of both companies, combining Immatics’ TCR platform with Moderna’s cutting-edge […]

Page 2 of 103‹123 4 ›»

Blog